Insulin-like growth factor system in cancer: novel targeted therapies

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Insulin-like growth factors (IGFs) are crucial for cellular processes, including growth, survival, and proliferation.
• The IGF system, mediated by the IGF-1 receptor (IGF-1R), plays a significant role in various cancers by promoting tumor progression and metastasis.
• IGF bioavailability, critical for their function, is tightly regulated by IGF binding proteins (IGFBPs).

Purpose of the Study:

• To review the multifaceted role of the IGF system in cancer development and progression.
• To explore novel therapeutic strategies targeting the IGF system for cancer treatment.
• To evaluate the potential of IGFBP-based therapies as an alternative to direct IGF-1R inhibition.

Main Methods:

• Comprehensive literature review of studies on the IGF system in cancer.
• Analysis of existing and emerging therapeutic approaches targeting IGF-1R and IGFBPs.
• Discussion of the limitations of current IGF-1R inhibitors, including antibodies and tyrosine kinase inhibitors.

Main Results:

• The IGF system significantly contributes to cancer hallmarks such as sustained proliferation, evasion of apoptosis, angiogenesis, and metastasis.
• IGF-1R signaling is implicated in tumor cell transformation and the metastatic cascade.
• IGFBPs modulate IGF bioavailability and activity, influencing tumor growth and spread.

Conclusions:

• Targeting the IGF system holds promise for novel cancer therapies.
• Blocking IGF action via IGFBPs presents a potentially superior therapeutic strategy compared to directly inhibiting IGF receptors.
• Further research into IGFBP-mediated inhibition could lead to the development of innovative and effective cancer treatments.